Likewise, insight into the molecular basis for hERG's anomalous gating properties, particularly the mechanisms of rapid onset and recovery from inactivation, as well the perturbation of inactivation in congenital short QT mutations, should greatly facilitate development of therapeutic interventions for SQTS (Hancox et al., 2018). This evidence concerns the gene KCNH2 and Familial short QT syndrome.